beta
Trial Radar IA
Lo studio clinico NCT07095920 per Ictus, Chronic Stroke Patients, Accidente cerebrovascolare (ACV) è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca

RESPARK - Brain Q for Chronic Stroke

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT07095920 è uno studio interventistico per Ictus, Chronic Stroke Patients, Accidente cerebrovascolare (ACV), attualmente in arruolamento. Avviato il 27 agosto 2025, prevede di arruolare 25 partecipanti. Sotto la guida di l'Università della Florida, dovrebbe concludersi entro il 1 dicembre 2026. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 19 settembre 2025.
Sommario breve
This trial tests a promising new intervention to promote post-stroke neural reorganization and functional recovery. The Q Therapeutic (BQ 3.0) is a wearable medical system that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. This trial is a prospective, single-arm, open-label, single center clinical trial designed to evaluate the safety, feasibility, and efficacy of the Q Therapeutic (BQ 3.0) System in the rehabilitation of people with chronic stroke.
Descrizione dettagliata
The study intervention will consist of a total of 5 sessions per week over a period of 3 months (12 weeks) for a total of up to 60 sessions. Each participant must complete at least 40 sessions over the 12-week period to complete the protocol. No extra time will be given to complete all 60 sessions. Each session will last up to 60 minutes during which 40 minutes of active stimulation using the BQ 3.0 System will be administered to participants. The 40 minutes of stimulation will be paired with seated upper extremity (UE) exercises. Lastly, the device will be removed and 10 minutes of standing balance and LE strengthening exercises will be performed without stimulation. A battery of clinical assessments will be conducted before and after the 60 exercise sessions.
Titolo ufficiale

Frequency-tuned Electromagnetic Field Treatment to Facilitate Recovery of Patients With Chronic Stroke

Condizioni
IctusChronic Stroke PatientsAccidente cerebrovascolare (ACV)
Altri ID dello studio
  • IRB202500526
Numero NCT
NCT07095920
Data di inizio (effettiva)
2025-08-27
Ultimo aggiornamento pubblicato
2025-09-19
Data di completamento (stimata)
2026-12
Arruolamento (previsto)
25
Tipo di studio
Interventistico
FASE
N.D.
Stato
In arruolamento
Parole chiave
BrainQ
Electromagnetic Stimulation
upper extremity
rehabilitation
exercise
mobility
Scopo principale
Trattamento
Allocazione
N.D.
Modello di intervento
A gruppo singolo
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
SperimentaleBQ3.0 Active Stimulation
60 sessions over a period of 12 weeks (5 treatments per week) of active study intervention with the BQ 3.0 (frequency and intensity parameters will be set to 1-100 Hz.; 0.1-1.0 G), including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
Device: Q Therapeutic System (BQ 3.0) - Active
The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Change in Fugl-Meyer Assessment - Upper Extremity
A performance measure used to assess arm function. 33 items are scored on a scale of 0 to 2, where 0=cannot perform, 1=performs partially and 2=performs fully. An increase in score reflects an improvement in arm function.
Baseline, 3 months after, and 6 months after start of interventions
Change from Baseline in Modified Rankin Scale (mRS)
A 7-point scale used to measure the degree of disability or dependence in daily activities of people who have suffered a stroke. Scores range from 0 (no symptoms) to 6 (death). A decrease in score reflects a reduction in disability and improved independence.
Baseline, 3 months after, and 6 months after the start of interventions
Esito secondario
Misure di esitoDescrizione della misuraArco temporale
Cumulative incidence of adverse events
The number of adverse events reported throughout the study.
Initial consent through final study visit (6 months)
Criteri di eleggibilità

Età idonea
Adulto, Adulto anziano
Età minima
18 Years
Sessi idonei
Tutti
  1. Upper Extremity Fugl-Meyer Assessment score between 22-50 (inclusive) of impaired limb.
  2. Upper Extremity Fugl-Meyer Assessment score is within up to 3-point difference between Screening and Baseline visit.
  3. Age 18 to 80 years of age (inclusive).
  4. Stroke due to ischemia or to intracerebral hemorrhage.
  5. >6 months to 5 years from stroke onset.
  6. Box & Block Test score with affected arm is ≥1 block in 60 seconds.
  7. Able to sit with the investigational system for 40 consecutive minutes.
  8. Can follow a 3-step command, such as "take the paper, fold it in half, and return it to me", or a non-verbal equivalent.
  9. Willingness to participate in physical exercises during study intervention sessions.
  10. Availability of a relative or other caregiver that is able to participate in training and assist during treatment sessions at Brooks and home during the study duration.
  11. If female, not pregnant or breastfeeding or planning pregnancy during the study period.
  12. The subject is able to provide Informed consent.

  1. Severe neglect impairment interfering with assessments or treatments.
  2. Severe depression, defined as Geriatric Depression Scale (GDS) Score >10/15
  3. Presence of implanted or retained MR-incompatible devices or materials, or the presence of life-sustaining MR-compatible devices (e.g. pacemaker or internal cardiac defibrillator).
  4. Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years
  5. Botulinum toxin to the paretic arm: received in the prior 3 months OR expected before the 6-Month Visit
  6. Severe upper extremity spasticity, defined as presence of contracture or modified Ashworth Scale score ≥3 in either biceps or pectoralis
  7. Pre-existing neurological condition (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or physical limitation that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  8. Significant visual disturbances, pre-existing or resulting from the index stroke, that cannot be corrected and that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  9. Unstable serious illness/condition (e.g., active cancer, severe heart failure, active major psychiatric condition) or life expectancy of less than 12 months.
  10. Alcohol abuse and/or illicit drug abuse in the past 6 months, which is likely to influence ability to fully participate in the trial.
  11. Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.
  12. Active participation in an upper extremity rehabilitation program provided by a licensed provider within 4 weeks from the screening visit and until the primary endpoint visit.
  13. Employee of the Sponsor.
  14. Prisoner.
University of Florida logoUniversità della Florida295 studi clinici attivi da esplorare
  • BrainQ Technologies Ltd. logoBrainQ Technologies Ltd.
  • Brooks Rehabilitation logoBrooks Rehabilitation
Contatti principali dello studio
Contatto: Emily J Fox, PT, DPT, MHS, PhD, 904-742-2500, [email protected]
Contatto: Jennifer Brooke Hoisington, MSPT, 904-659-3733, [email protected]
1 Centri dello studio in 1 paesi

Florida

Brooks Rehabilitation Clinical Research Center, Jacksonville, Florida, 32216, United States
Jennifer Brooke Hoisington, MSPT, Contatto, 904-659-3733, [email protected]
Emily J Fox, PT, DPT, MHS, PhD, Investigatore principale
In arruolamento